JP2023546970A5 - - Google Patents

Info

Publication number
JP2023546970A5
JP2023546970A5 JP2023525457A JP2023525457A JP2023546970A5 JP 2023546970 A5 JP2023546970 A5 JP 2023546970A5 JP 2023525457 A JP2023525457 A JP 2023525457A JP 2023525457 A JP2023525457 A JP 2023525457A JP 2023546970 A5 JP2023546970 A5 JP 2023546970A5
Authority
JP
Japan
Prior art keywords
subject
cyp
beta
hydroxylase inhibitor
plasma
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023525457A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023546970A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/056499 external-priority patent/WO2022093714A1/en
Publication of JP2023546970A publication Critical patent/JP2023546970A/ja
Publication of JP2023546970A5 publication Critical patent/JP2023546970A5/ja
Pending legal-status Critical Current

Links

JP2023525457A 2020-10-26 2021-10-25 高血圧のためのｃｙｐ１１ｂ２ベータヒドロキシラーゼ阻害剤 Pending JP2023546970A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063105745P 2020-10-26 2020-10-26
US63/105,745 2020-10-26
US202163223719P 2021-07-20 2021-07-20
US63/223,719 2021-07-20
PCT/US2021/056499 WO2022093714A1 (en) 2020-10-26 2021-10-25 Cyp11b2 beta hydroxylase inhibitors for hypertension

Publications (2)

Publication Number Publication Date
JP2023546970A JP2023546970A (ja) 2023-11-08
JP2023546970A5 true JP2023546970A5 (https=) 2024-10-30

Family

ID=81384356

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023525457A Pending JP2023546970A (ja) 2020-10-26 2021-10-25 高血圧のためのｃｙｐ１１ｂ２ベータヒドロキシラーゼ阻害剤

Country Status (4)

Country Link
US (1) US20240009201A1 (https=)
EP (1) EP4232011A4 (https=)
JP (1) JP2023546970A (https=)
WO (1) WO2022093714A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230069126A (ko) * 2020-09-15 2023-05-18 미쓰비시 타나베 파마 코퍼레이션 트리아진 화합물의 염, 그 결정형 및 제조 방법
CN117957213A (zh) * 2021-07-20 2024-04-30 矿物疗法公司 包括经二取代的1,2,4-三嗪化合物的盐的可溶性药物组合物
TW202339758A (zh) * 2022-01-19 2023-10-16 美商礦物質醫療股份有限公司 藉由週期性遏制醛固酮合酶治療高血壓之方法
JP2025527706A (ja) * 2022-08-23 2025-08-22 ミネラリス・セラピューティクス・インコーポレイテッド 肥満対象における高血圧を治療する方法
CA3265668A1 (en) * 2022-08-23 2024-02-29 Mineralys Therapeutics, Inc. METHODS OF TREATING HYPERTENSION WITH A COMBINATION OF AN ALDOSTERONE SYNTHASE INHIBITOR AND A DIURETIC
KR20250057804A (ko) 2022-09-02 2025-04-29 애프니메드, 인코포레이티드 (델라웨어) 수면 무호흡증을 치료하기 위한 방법 및 조성물
WO2025059569A1 (en) * 2023-09-15 2025-03-20 Mineralys Therapeutics, Inc. Process for producing triazine compound
CN120904169A (zh) * 2024-05-30 2025-11-07 浙江扬厉医药技术有限公司 一种n-烷氧基乙酰胺类化合物、其药物组合物及其应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ596302A (en) * 2009-05-15 2014-01-31 Novartis Ag Aryl pyridine as aldosterone synthase inhibitors
DE102012200360A1 (de) * 2012-01-11 2013-07-11 Bayer Intellectual Property Gmbh Substituierte Triazine und ihre Verwendung
JP6067181B2 (ja) * 2013-04-30 2017-01-25 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング アルドステロンシンターゼ阻害薬
MY176401A (en) * 2014-04-24 2020-08-05 Mitsubishi Tanabe Pharma Corp Novel disubstituted 1,2,4-triazine compound
JP6314196B2 (ja) * 2015-10-22 2018-04-18 田辺三菱製薬株式会社 医薬組成物

Similar Documents

Publication Publication Date Title
JP2023546970A5 (https=)
Sullivan et al. Hemodynamic and antihypertensive effects of captopril, an orally active angiotensin converting enzyme inhibitor.
HK1079997A1 (zh) 治疗接受激素替代疗法之妇女中的高血压的方法
WO2007098390A2 (en) Method for treating resistant hypertension
EP1993541A2 (en) Antihypertensive therapy
VAUGHAN jR et al. Hemodialysis-resistant hypertension: control with an orally active inhibitor of angiotensin-converting enzyme
JP2011190199A (ja) 関節リウマチ薬
CN110545819A (zh) 用于治疗高血压的组合物
Larochelle et al. Effect of captopril (SQ 14225) on blood pressure, plasma renin activity and angiotensin I converting enzyme activity
FROLICH et al. Reduction of plasma renin activity by inhibition of the fatty acid cyclooxygenase in human subjects: independence of sodium retention
JP2025503015A5 (https=)
Oparil et al. Effects of candesartan cilexetil in patients with severe systemic hypertension
Staessen et al. Double-blind comparison between propranolol and bendroflumethiazide in captopril-treated resistant hypertensive patients
EP2446885B1 (en) Therapeutic agent for hypertension or normal high blood pressure
Bălan et al. Comparing different treatment schedules of Zomen (zofenopril)
EP2586442A1 (en) Sustained-release therapeutic agent for hypertension and renal dysfunction
US20250302802A1 (en) Methods and compositions
Fuenfstueck et al. Efficacy and safety of combination therapy using high-or low-dose hydrochlorothiazide with valsartan or other angiotensin-receptor blockers
ES2332884T3 (es) Tratamiento de la lipodistrofia con inhibidores del sistema renina angiotensina.
TW202416996A (zh) 治療肥胖個體之高血壓的方法
TW202416985A (zh) 醛固酮合酶抑制劑與利尿劑組合治療高血壓之方法
RU2515482C1 (ru) Способ профилактики развития мозговых нарушений и осложнений сердечно-сосудистых заболеваний в предгипертоническом состоянии
KR20250084121A (ko) 매일 1회 복용 알도스테론 합성효소 저해제 (R)-(+)-5-(p-시아노페닐)-5,6,7,8-테트라하드로이미다조[1,5-a]피리딘
TW201330848A (zh) 治療黑種病人高血壓之方法
JP2012254975A (ja) Ａｃｅ阻害剤とｌ−アルギニンを含有する医薬組成物